$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts
[Published by Current Partnering]

Published by Current Partnering: 01 Oct 2016 | 373 | In Stock

Introduction

The Global Companion Diagnostics Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in companion diagnostics partnering deals

Companion diagnostics partnering agreement structure

Companion diagnostics partnering contract documents

Top companion diagnostics deals by value

Most active companion diagnostics dealmakers


The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.


This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.


The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.


The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 350 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.


Key benefits


Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:


In-depth understanding of Companion Diagnostics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies

Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies

Identify most active Companion Diagnostics dealmakers since 2010

Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Companion Diagnostics trends and structure of deals entered into by leading companies worldwide.


Companion Diagnostics Partnering Terms and Agreements includes:


Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010

Analysis of Companion Diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Companion Diagnostics deals

Access to Companion Diagnostics contract documents

Leading Companion Diagnostics deals by value since 2010

Most active Companion Diagnostics dealmakers since 2010


In Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:


Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 350 Companion Diagnostics deals.


Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts [Published by Current Partnering]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in Companion Diagnostics dealmaking

    2.1. Introduction

    2.2. Companion Diagnostics partnering over the years

    2.3. Most active Companion Diagnostics dealmakers

    2.4. Companion Diagnostics partnering by deal type

    2.5. Companion Diagnostics partnering by therapy area

    2.6. Deal terms for Companion Diagnostics partnering

    2.6.1 Companion Diagnostics partnering headline values

    2.6.2 Companion Diagnostics deal upfront payments7

    2.6.3 Companion Diagnostics deal milestone payments

    2.6.4 Companion Diagnostics royalty rates

    Chapter 3 – Leading Companion Diagnostics deals

    3.1. Introduction

    3.2. Top Companion Diagnostics deals by value

    Chapter 4 – Most active Companion Diagnostics dealmakers

    4.1. Introduction

    4.2. Most active Companion Diagnostics dealmakers

    4.3. Most active Companion Diagnostics partnering company profiles

    Chapter 5 – Companion Diagnostics contracts dealmaking directory

    5.1. Introduction

    5.2. Companion Diagnostics contracts dealmaking directory

    Chapter 6 – Companion Diagnostics dealmaking by technology type

    Chapter 7 – Partnering resource center

    7.1. Online partnering

    7.2. Partnering events

    7.3. Further reading on dealmaking

    Appendices

    Appendix 1 – Companion Diagnostics deals by company A-Z

    Appendix 2 – Companion Diagnostics deals by stage of development

    Discovery

    Preclinical

    Phase I

    Phase II

    Phase III

    Regulatory

    Marketed

    Formulation

    Appendix 3 – Companion Diagnostics deals by deal type

    Asset purchase

    Assignment

    Bigpharma outlicensing

    Co-development

    Collaborative R&D

    Co-market

    Co-promotion

    CRADA

    Cross-licensing

    Development

    Distribution

    Equity purchase

    Evaluation

    Grant

    Joint venture

    Licensing

    Litigation

    Manufacturing

    Marketing

    Material transfer

    Option

    Promotion

    Research

    Settlement

    Spin out

    Sub-license

    Supply

    Technology transfer

    Termination

    Warranty

    Appendix 4 – Companion Diagnostics deals by therapy area

    Appendix 5 –Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    Table of figures

    Figure 1: Companion Diagnostics partnering since 2010

    Figure 2: Active Companion Diagnostics dealmaking activity– 2010 to 2016

    Figure 3: Companion Diagnostics partnering by deal type since 2010

    Figure 4: Companion Diagnostics partnering by disease type since 2010

    Figure 5: Companion Diagnostics deals with a headline value

    Figure 6: Companion Diagnostics deals with an upfront value

    Figure 7: Companion Diagnostics deals with a milestone value

    Figure 8: Companion Diagnostics deals with a royalty rate value

    Figure 9: Top Companion Diagnostics deals by value since 2010

    Figure 10: Most active Companion Diagnostics dealmakers 2010 to 2016

    Figure 11: Online partnering resources

    Figure 12: Forthcoming partnering events

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

373 | CP2106

Number of Pages

248

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Companion Animal Care Market: Size, Trends & Forecasts (2017-2021)
Scope of the ReportThe report entitled “Global Companion Animal Care Market: Size, Trends & Forecast...
01 Feb 2017 by Daedal Research USD $800 More Info
Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Fluoroquinolone), Mode of Delivery (Premixes, Oral Powder, Injection), Animal (Food-producing & Companion) - Global Forecast to 2021
The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from ...
12 Dec 2016 by MarketsandMarkets USD $5,650 More Info
Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines), and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)
The veterinary vaccines market has seen significant growth over the past few years, due to fear of i...
01 Dec 2016 by Market Data Forecast USD $4,255 More Info
North America Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)
The North America animal vaccines market is poised to reach 71.69 Million by 2020 from 07.26 M...
01 Dec 2016 by Market Data Forecast USD $3,335 More Info
Europe Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)
The Europe animal vaccines market is poised to reach 40.82 Million by 2020 from 93.64 Million ...
01 Dec 2016 by Market Data Forecast USD $3,335 More Info
Asia-Pacific Veterinary Vaccines Market by Type (Livestock Vaccines and Companion Vaccines), by Technology (live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines) and by region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)
The Asia-Pacific animal vaccines market is poised to reach 03.27 Million by 2020 from 9.72 Mil...
01 Dec 2016 by Market Data Forecast USD $3,335 More Info
Trends and Innovations in Companion Diagnostics
IntroductionAre companion diagnostics becoming a “must have” for market access? Companion Diagnostic...
01 Apr 2016 by FirstWord Pharma USD $695 More Info
Veterinary / Animal Vaccines Market by Product (Livestock, Companion, Poultry, Equine, Porcine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Swine& Avian Influenza, Strangles) & Technology (Live attenuated, DNA, Inactivated) - Global Forecast to 2020
The report segments the veterinary vaccines market on the basis of products, diseases, technologies,...
09 Jun 2015 by MarketsandMarkets USD $5,650 More Info
Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them?
ScopeAs exemplified by Roche's R&D presentation last week (see Spotlight On: Roche's R&D day – The k...
01 Oct 2013 by FirstWord Pharma USD $695 More Info
Effective sales and marketing strategies for drugs with companion diagnostics
IntroductionTo fully exploit the commercial advantages of companion diagnostics, Pharma companies ne...
01 May 2013 by FirstWord Pharma USD $695 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts [Published by Current Partnering] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Bizwit Research and Consulting
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)
  • VPA Research